Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Clinical trial NCT05270668 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05270668
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-29
- Primary completion
- 2026-04-16
- Enrollment
- 154
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.